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Summary
Background:  Occult  hepatitis  B  viral  infection  is  the  presence  of  hepatitis  B  viral
nucleic  acids  in  the  serum  and/or  liver  in  the  absence  of  hepatitis  B  surface  antigen.
Aim:  The  study  aimed  to  determine  the  prevalence  of  occult  hepatitis  B  virus  infec-
tion  among  hepatitis  C  virus-negative  hemodialysis  patients  and  to  identify  their
genotypes.
Methods:  of  144  patients  on  maintenance  hemodialysis,  50  hepatitis  B  surface  anti-
gen  and  hepatitis  C  virus  nucleic  acid-negative  patients  were  selected  according  to
strict  inclusion  criteria  to  avoid  the  effect  of  confounding  variables.  The  following
investigations  were  done:  serum  AST  and  ALT;  HBsAg;  HBcAb;  HCV-Ab;  HCV-RNA;  and
HBV-DNA.
Results:  Positive  hepatitis  B  viral  nucleic  acid  was  conﬁrmed  in  12/144  (8.3%)
hemodialysis  patients  and  12/50  (24%)  in  our  study  group  (occult  infec-
tion).  Mean  hemodialysis  periods  for  negative  patients  and  occult  hepatitis  B
virus  patients  were  27.3  ±  18.8  and  38.4  ±  8.14  months,  respectively,  and  this
Abbreviations: HBV, hepatitis B virus; OBI, occult HBV infection; HBsAg, hepatitis B surface antigen; PCR, polymerase chain
reaction; ESRD, end-stage renal disease.
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difference  was  signiﬁcant  (p-value  =  0.02).  Mean  alanine  transaminase  levels  were
20.27  ±  5.5  IU/L  and  25.3  ±  9.6  in  negative  patients  and  occult  infection  patients,
respectively.  This  difference  was  non-signiﬁcant.  Aspartate  transaminase  levels  were
21.4  ±  10.2  IU/L  and  27.3  ±  4.6  IU/L,  respectively,  in  negative  patients  and  infected
patients;  this  difference  was  signiﬁcant  (p-value  = 0.03).  Half  (6/12)  of  the  positive
samples  belonged  to  genotype  ‘B’,  33.3%  (4/12)  to  ‘C’,  and  16.6%  (2/12)  to  genotype
‘D’.
Conclusion:  OBI  is  likely  among  hemodialysis  patients  even  without  HCV  coinfection
(24%).  Genotype  D  cannot  be  the  only  genotype  distributed  in  Upper  Egypt,  as  the
elatively  new  results  that  50%  of  the  patients  with  occult  B
 carry  genotype  C  and  only  16.6%  carry  genotype  D.
dulaziz  University  for  Health  Sciences.  Published  by  Elsevier
ed.
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sis on  their  histories  of  blood  transfusions,  liver
diseases and  durations  of  hemodialysis.  Clinicalcurrent  study  reported  r
carry  genotype  B,  33.3%
©  2015  King  Saud  Bin  Ab
Limited.  All  rights  reserv
ackground
epatitis  B  virus  (HBV)  infection  is  a  global
ealth concern  with  multiple  clinical  presenta-
ions, e.g.,  occult  HBV  infection  (OBI)  [1]. OBI
s deﬁned  as  the  presence  of  a  low  amount  of
BV DNA  (less  than  104 copies/mL)  in  patients
ith negative  hepatitis  B  surface  antigen  (HBsAg)
erum/plasma [2].  The  risk  of  infection  transmis-
ion from  OBI  through  blood  transfusion  could  be
voided by  utilization  of  highly  sensitive  poly-
erase  chain  reaction  (PCR)-based  techniques,
hich can  identify  HBV  DNA  in  HBsAg-negative  indi-
iduals [3].
OBI  is  highly  prevalent  among  patients  with
nd-stage renal  disease  (ESRD)  on  maintenance
emodialysis  because  of  frequent  blood  transfu-
ions [4].  ESRD  is  a  serious  problem  globally;
owever, the  prevalence  is  higher  in  developing
ountries, especially  in  the  Middle  East  [5].
The exact  cause  of  OBI  is  not  understood.  Several
tudies have  suggested  that  OBI  could  be  caused  by
utant viruses  that  cannot  be  detected  by  current
BsAg assays.  Other  studies  have  suggested  that
BI could  be  due  to  a  failure  of  viral  replication,
ene expression,  or  virus  release  [6]. HBV  has  been
lassiﬁed  into  ten  genotypes  (labeled  A—J)  [7];
ome genotypes  are  associated  with  different  clini-
al outcomes.  Genotypes  C  and  D  generally  tend  to
e related  to  more  severe  prognosis  (particularly
epatocellular  carcinoma)  than  genotypes  A  and  B
8].  Real-time  PCR  using  genotype-speciﬁc  primers
s a  very  important  technique  because  ﬂuorescent
robes allow  for  the  highly  sensitive  detection  and
uantiﬁcation  of  HBV  DNA,  while  melting  curve
nalysis allows  the  determination  of  genotypes,
hich aids  in  the  prediction  of  therapeutic  out-
omes  [9].
e
sDifferent  HBV  genotypes  have  different  geo-
raphic distributions.  The  HBV  genotype  D  is
ommon  in  Mediterranean  area  data  [10]. Screening
f OBI  in  hemodialysis  patients  in  Egypt  is  limited
11], and  little  information  exists  about  the  relation
etween  the  HBV  genotypes  and  OBI  in  Egypt  [12].
herefore, we  investigated  the  prevalence  of  OBI
ccurrence  without  HCV-coinfection  among  Egyp-
ian hemodialysis  patients,  and  we  identiﬁed  their
ifferent  genotypes  using  a  highly  sensitive  and  spe-
iﬁc quantitative  PCR  assay.
aterials and methods
atients
he  study  included  all  patients  (144)  on  main-
enance hemodialysis  (more  than  six  months)
ecruited from  Minia  University  Hospital  (MUH)  at
he time  of  the  study.  Serum  samples  were  rou-
inely collected  for  the  detection  of  HCV  antibodies
nd Hepatitis  B  surface  Antigen  (HBsAg)  before  the
tart of  dialysis.  Exclusion  criteria  for  our  study
as included:  1  —  acute  or  chronic  HBV  infec-
ion, as  determined  by  positive  Hepatitis  B  core
ntibodies  (anti  HBc)  and  HBsAg,  respectively;  2
 HBV  vaccination  history  (to  exclude  vaccine-
nduced immunity);  and  3  —  HCV  RNA  and  HCV
ntibodies, to  exclude  coinfection  with  HCV  and
ther liver  diseases.
A  full  history  was  collected  from  the  selected
roup of  patients  (50/144  patients)  with  empha-xaminations were  conducted  with  emphasis  on
igns of  chronic  liver  disease,  e.g.,  jaundice,
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palmar  erythema,  lower  limb  edema,  hepatomeg-
aly, splenomegaly  or  ascites.
Their ages  ranged  from  29  to  63  years.  Thirty-one
(62%) of  the  participants  were  males  while  19  (38%)
were females,  thirty-six  (72%)  of  the  patients  were
rural residents,  while  14  were  residents  of  urban
areas (28%).
The study  protocol  was  approved  by  the  Ethical
Committee of  Minia  Faculty  of  Medicine.  Written
informed consent  was  obtained  from  all  partici-
pants prior  to  participation  in  the  study.  The  study
was conducted  in  accordance  with  the  ethical
guidelines of  the  1975  Declaration  of  Helsinki.
Whole blood  samples  (5  mL)  were  collected
under completely  aseptic  conditions  and  processed
within 2  h  for  the  separation  of  plasma  by  gradi-
ent centrifugation.  The  plasma  was  gently  removed
from the  uppermost  layer  with  pipette  in  ster-
ile Eppendorf  and  stored  at  −20 ◦C  until  further
processing. Serological  markers  of  HBV  infec-
tion (HBsAg,  anti-HBc)  were  determined  using
standard third-generation  commercially  available
enzyme  immunoassays  (Abbott  GmbH,  Wiesbaden-
Delkenheim, Germany).
ALT  and  AST  were  carried  out  using  Biocon
standard kits,  and  DAX-48  autoanalyzers  were  used
to measure  AST  and  ALT  activities  in  plasma  samples
according  to  the  literature  [13].
Detection of HBV DNA by quantitative real
time-PCR
DNA  extraction
DNA extraction  was  performed  according  to
manufacturer’s instructions  (HBV  extraction  kits)
(Liferiver,  Shanghai  ZJ  Bio-Tech  Co.,  Ltd,  China)
using  50  l plasma.
Identiﬁcation  of  HBV  DNA:  plasma
HBV DNA  was  quantiﬁed  by  the  Determination  Kit
for hepatitis  B  virus  DNA  (Life  River,  China)  with  a
detection limit  of  1  × 102 IU/mL,  according  to  the
manufacturer’s instructions.  All  of  the  applied  kits
were speciﬁcally  ready-to-use  systems  that  worked
based on  ﬂuorogenic  5′ nuclease  assays  using  spe-
ciﬁc primers  and  probes,  provided  by  kits.  Positive
and negative  controls  were  included  at  each  step.
Applied  Biosystems  7500  Fast  Real-Time  PCR  Ther-
mal cyclers  (Life  Technologies,  USA)  were  used.
Assays  were  repeated  after  a  dilution  of  1:1000.  The
assay results  were  compared  with  those  of  the  kit’s
positive  controls.
r
n
p
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etection of the HBV-DNA genotype
enotyping  was  performed  on  patients  diagnosed
s having  OBI  using  HBV  genotyping  real  time-PCR
its (Liferiver,  Shanghai  ZJ  Bio-Tech  Co.,  Ltd,  China)
ccording  to  the  manufacturer’s  protocol,  and  the
esults were  compared  with  those  of  the  kit’s  posi-
ive controls.
tatistical  analysis
ata  were  analyzed  by  SPSS  version  10,  using
escriptive statistics  (mean  ±  standard  deviation)
nd the  chi-squared  test  for  comparison  of  qual-
tative  variables.  p-values  <0.05  were  considered
tatistically signiﬁcant.
esults
etection of OBI and HBV-DNA genotypes
he  study  samples  (50/144)  of  patients  (who  were
egative  for  all  of  the  following  tests,  anti-HCV,
BsAg, HBcAg  and  HCV  RNA),  were  examined  for
BI by  quantitative  real-time-PCR.  Positive  HBV
NA was  conﬁrmed  in  12  out  of  144  (8.3%)  of
emodialysis patients,  as  the  deﬁnition  of  OBI
ncludes  the  absence  of  HBsAg  only.  Incidence  rates
f OBI  among  HBsAg  and  Anti  HCV  negative  patients
ould  be  12  out  of  50  (24%)  in  our  group  of  patients.
he genotyping study
he  genotyping  study  was  conducted  on  samples
f 12  HBV  DNA-positive  patients  as  described  in
he materials  and  methods  section.  Genotype  B
as predominant  in  HBV  DNA-positive  samples,
hich constituted  6/12  samples  (50%).  However,
BV genotypes  C and  D  were  observed  in  33.33%
nd 16.66%  of  samples,  respectively,  as  shown  in
igs.  1  and  2 and  Table  2.
s summarized in Table 1
s  summarized  in  Table  1, the  mean  age  of  the  nega-
ive patients  was  46.96  ±  11.02  years,  and  the  mean
ge of  the  OBI  positive  patients  was  49.81  ±  13.15
ears. Males  constituted  23/38  (65.2%)  of  the
egative  patients  and  66.6%  (n  =  8/12)  of  the
BI positive  patients.  Twenty-eight  (73.67%)  of
he negative  patients  were  rural  residents,  and
ight (66.6%)  of  the  OBI  positive  patients  were
ural residents.  These  results  were  statistically
on-signiﬁcant  (p-value  >  0.05).  Mean  hemodialysis
eriods for  negative  patients  and  occult  hepatitis
 virus  patients  were  27.3  ±  18.8  and  38.4  ±  8.14
Genotyping  of  occult  hepatitis  B  virus  455
Figure  1  Gene  typing  of  different  ampliﬁcation  plots.
Table  1  Clinical  and  laboratory  characteristics  of  the  study  patients.
Characteristics  OBI  negative  patients  OBI  patients  p  value
Number  38  (76%)  12  (24%)
Age  (mean  ±  SD) 46.96 ±  11.02 49.81  ±  13.15  0.5
Sex  (male)  (n/%) 23  (65.2%)  8  (66.6%)  0.3
Residence  (rural)  (n/%) 28  (73.67%) 8  (66.6%)  0.1
Duration  of  hemodialysis  (months,  mean  ±  SD) 27.3 ±  18.8 38.4 ±  8.14 0.02*
Positive  history  of  transfusion  (%) 25  (65.67%) 2  (16.6%) 0.06
History  of  liver  disease 0  0
ALT  (IU/L) 20.27  ±  5.5 25.3 ±  9.6  0.07
AST  (IU/L) 21.4  ±  10.2 27.3 ±  4.6 0.03*
p value; *signiﬁcant (<0.05); **highly signiﬁcant (<0.01). Abbreviati
OBI; occult hepatitis B virus infection; SD, standard deviation.
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by PCR  in  10/49  (20.4%)  hemodialysis  patientsigure  2  Genotypes  of  occult  hepatitis  B  virus  infection
n  hemodialysis  patients.
onths,  respectively,  which  was  a  signiﬁcant  dif-
erence (p-value  =  0.02).  Mean  ALT  liver  enzyme
evels were  20.27  ±  5.5  IU/L  and  25.3  ±  9.6  IU/L  in
egative  patients  and  occult  infection  patients,
espectively, which  was  non-signiﬁcant.  AST  levels
ere 21.4  ±  10.2  IU/L  and  27.3  ±  4.6  IU/L  in  nega-
ive patients  and  infected  patients,  respectively,
hich was  a  signiﬁcant  difference  (p-value  =  0.03)
Table  2).
[
h
ions: AST, aspartate transaminase; ALT, alanine transaminase;
iscussion
lood-transmitted  hepatitis  viruses  are  consider-
ble problems  in  developing  countries.  Egypt  has
een reported  to  be  an  endemic  country  for  HCV
nfection  and  is  considered  as  an  intermediate  area
or HBV  infection  [14].
Our study  aimed  to  investigate  the  prevalence
f OBI  occurrence  without  HCV  coinfection  among
gyptian  hemodialysis  patients.  Exclusion  criteria
or our  study  included  acute  or  chronic  HBV  infec-
ion, HBV  vaccination  history  as  determined  by
ositive Hepatitis  B  core  antibodies  (anti  HBc),
BsAg,  HCV  RNA  and  HCV  antibodies  to  exclude
oinfection with  HCV  and  other  liver  diseases.
e also  excluded  patients  with  an  HBV  vaccina-
ion history  to  avoid  vaccine-induced  immunity.  We
ound that  OBI  was  detected  in  12/50  (24%)  of our
atients.  Similar  results  have  been  reported  by  Sia-
ris et  al.,  who  reported  that  HBV  DNA  was  detected15]. However  previous  studies  in  dialysis  units
ave reported  a lower  prevalence,  where  OBI  was
dentiﬁed  in  2.7%  (5/188)  in  Turkey  [16]  and  3.8%
456  M.A.  Esmail  et  al.
Table  2  Levels  of  DNA  quantity  of  different  genotypes  in  plasma  in  IU/L.
Genotype  Minimum  (IU/L)  Maximum  (IU/L)  Mean  (IU/L)
B  5  ×  102 4  ×  103 1320
C  1.5  ×  106 6  ×  106 3.3750E6
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(9/239)  of  HBs-Ag-negative  North  American  adult
hemodialysis  patients  using  real-time  PCR  [17].
In Egypt,  Abu  El  Makarem  et  al.  [11]  demon-
strated that  3%  of  ESRD  patients  with  HCV
RNA-negative  and  HBsAg-negative  reports  from
Upper Egypt  had  OBI.  Other  studies  have  revealed
a higher  prevalence  of  OBI  in  hemodialysis  patient.
For example,  Besisik  [18]  reported  that  positive
HBV DNA  and  HBsAg-negative  (OBI)  was  detected  in
36% (12/33)  of  patients.  However,  in  this  study,  only
9.1% (3/33)  of  hemodialysis  patients  had  a  history  of
HBV vaccination.  The  fact  that  a  higher  prevalence
of OBI  is  detected  in  hemodialysis  patients  with  no
history of  HBV  vaccination,  suggests  that  the  lack  of
past HBV  vaccination  could  be  an  important  risk  fac-
tor. This  difference  may  explain  the  high  prevalence
of OBI  in  hemodialysis  patients  in  our  study  because
we speciﬁcally  excluded  the  vaccinated  patients.
These discrepancies  in  the  rates  of  OBI  in  hemodial-
ysis patients  may  reﬂect  the  diverse  prevalence  of
HBV infection  in  hemodialysis  patients,  in  differ-
ent countries,  and  within  different  dialysis  units
in different  clinical  situations.  Additionally,  conse-
quential differences  in  the  composition  of  the  study
populations  and  sensitivity  of  the  techniques  used
for HBV-DNA  detection  may  lead  to  variations  in
prevalence  [15].  In  the  current  study,  OBI  was  not
signiﬁcantly  associated  with  age,  sex,  residence,
history of  hepatitis,  history  of  blood  transfusions,
or ALT  levels.  However,  there  were  signiﬁcant  asso-
ciations  between  the  presence  of  HB-VDNA  and  the
length of  hemodialysis  periods,  and  HBV-DNA  pos-
itivity and  AST  levels,  which  largely  agreed  with
previous  studies  in  Egypt  [11]. The  determination  of
HBV genotypes  is important  because  HBV  genotypes
are associated  with  the  course  of  the  infection,
the response  to  antiviral  treatment  regimens  and
the clinical  prognosis  [19]. In  Egypt,  there  have
been few  reports  about  the  predominant  geno-
types of  HBV.  The  D  genotype  has  been  reported
as the  predominant  type,  e.g.,  Zaky  et  al.,  who
studied clinicopathologic  features  and  genotyping
in patients  with  chronic  HBV  infection  in  the  Upper
Egypt and  Ragheb  et  al.,  who  studied  intra-familial
transmission patterns  of  the  hepatitis  B  virus  geno-
type [20,21].  However,  our  study  revealed  that
the predominant  genotypes  of  HBV  were  mainly  B
(50%), followed  by  C  (33%)  and  D  (17%)  in  our  OBI
m
G
h
y1  ×  105 53  333.3333
atients.  These  ﬁndings  suggest  that  genotype  B  is
ore likely  to  disseminate  in  hemodialysis  environ-
entally.  The  differences  between  our  ﬁndings  and
hese others  may  have  contributed  to  the  different
ype of  samples  evaluated.  While  our  samples  were
rom a  selected  group  (anti  HBc,  HBsAg,  HCV  RNA
nd HCV  antibody-negative  results),  the  majority  of
he previous  studies’  published  samples  have  been
erived from  patients  with  established  chronic  dis-
ase [20,21]. Another  study  in  Egypt  carried  out
n hemodialysis  patients  reported  that  the  geno-
ype D  was  not  predominant.  They  reported  that
he C  genotype  was  present  in  a  plurality  (44.4%),
ollowed by  A  (27.8%)  and  B  (22.2%),  of  hemodialy-
is patients  [22]. Thus,  a new  pattern  of  genotypes
ay appear  in  Egypt  or may  be  present  in  hemodial-
sis patients,  which  may  be  associated  with  genetic
ariations,  mutations  or  other  causes.  Thus,  further
enotyping  studies  should  be  performed.  It  was  dif-
cult to  demonstrate  a clear  association  between
BV genotypes  and  the  viral  load  because  of  the
mall number  of  genotypes.
onclusion
e  can  conclude  that  OBI  is  a  likely  nosoco-
ial infection  among  hemodialysis  patients  even
n the  absence  of  HCV  coinfection  (24%).  The  pro-
onged  duration  of  hemodialysis  is  a  major  risk
actor for  acquiring  the  infection;  thus,  incorpo-
ation of  sensitive  molecular  techniques  beside
erological  analysis  are  required  for  earlier  dis-
overy  and  interference.  Additionally,  the  study
as illustrated  that  HBV  genotype  D cannot  be  the
nly genotype  distributed  in  Upper  Egypt,  as  our
tudy found  that  50%  of  the  patients  with  occult
 carry  genotype  B,  33.3%  carry  genotype  C,  and
nly 16.6%  carry  genotype  D.  Extensive  epidemio-
ogical studies  for  genotyping  should  be  performed
o track  the  source  of  infections.  OBI  rates  reported
erein  are  very  high  compared  to  several  other
eveloped countries.  These  high  rates  are  an  impor-
ant source  of  nosocomial  HBV  transmission  and
ay induce  the  transmission  of  new  genotypes.
iven the  frequency  of  dialysis  and  the  uniquely
igh prevalence  of  HBV  among  Egyptian  hemodial-
sis patients,  we  think  that  patient  isolation
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particularly  those  known  to  have  HBV  infection)  is
ery important  in  Egypt,  in  addition  to  the  standard
ygienic  precautions.
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